[Mononucleosis syndrome with viro-immunologic parameters similar to those of a primary HIV-1 infection after interruption of highly effective anti-retroviral treatment].
Orbea Ríos
L
L
Domínguez Castellanos
A
A
Justo Alpañés
E
E
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D016516:CD4-CD8 Ratio; D003863:Depression / Q000150:complications; D016049:Didanosine / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1; D006801:Humans; D007244:Infectious Mononucleosis / Q000097:blood / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D008297:Male; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D018119:Stavudine / Q000627:therapeutic use; D016312:Treatment Refusal; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use; D019562:Viral Load; D014766:Viremia / Q000150:complications* / Q000188:drug therapy; D016047:Zalcitabine / Q000627:therapeutic use; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D016047:Zalcitabine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D018119:Stavudine; D016049:Didanosine; D019438:Ritonavir